Dr. Dale Bredesen
Changing the world of Alzheimer’s Disease Research
An internationally recognized expert in the mechanisms of neurodegenerative diseases, Dr. Dale Bredesen’s career has been guided by a simple idea: that Alzheimer’s as we know it is not just preventable, but reversible. Thanks to a dedicated pursuit of finding the science that makes this a reality, this idea has placed Dr. Bredesen at the vanguard of neurological research and led to the discoveries that today underlie the ReCODE Report.
Dr. Bredesen earned his MD from Duke University Medical Center and served as Chief Resident in Neurology at the University of California, San Francisco (UCSF), before joining Nobel laureate Stanley Prusiner’s laboratory at UCSF as an NIH Postdoctoral Fellow. He held faculty positions at UCSF, UCLA, and the University of California, San Diego. Dr. Bredesen also directed the Program on Aging at the Burnham Institute before joining the Buck Institute in 1998 as founding President and CEO.
Dr. Bredesen’s research explores previously uncharted territory in explaining the physical mechanism behind the erosion of memory seen in Alzheimer’s disease, and has opened the door to new approaches to treatment. This work has led to the identification of several new therapeutic processes that are showing remarkable early results. Dr. Bredesen is a prodigious innovator in medicine, with over thirty patents to his name. Notably, he put much of his findings and research into the 2017 New York Times‘ Best-Seller, The End of Alzheimer’s.
A cognoscopy is a term coined by Dr. Bredesen, that refers to a simple assessment, which uses a combination of laboratory and cognitive testing that identifies the contributors to cognitive decline or risk for decline. We all know that, when we turn 50 years old, we should have a colonoscopy, so that we can detect and treat colon cancer early, thus avoiding advanced, life-threatening cancer. But what about our brains? Just as with colon cancer, the pathology behind neurodegeneration, including Alzheimer’s, takes many years — often decades — to develop, providing for an extended prodromal period in which we can effectively intervene. The good news is that we can now check our risk and intervene as early as possible to identify if we have emerging contributors that are silently contributing to neurodegenerative pathology. We can do this by following three simple steps. Learn more.
Watch Dr. Dale Bredesen, Alzheimer’s disruptor, present his “Bold Vision” for reversing & preventing AD at his TEDx talk in Manhattan Beach.
With inspiring stories from patients who have reversed cognitive decline and are now thriving, this book shifts the treatment paradigm and offers a new and effective way to enhance cognition.
Taking insights gleaned from over 40 years in medicine, Dr. Bredesen has authored a groundbreaking guide to prevent and reverse Alzheimer’s disease that fundamentally changes how we understand cognitive decline.
Report of 100 patients, treated by several different physicians, with documented improvement in cognition, in some cases with documentation of improvement in electrophysiology or imaging, as well. This additional report provides further support for a randomized, controlled clinical trial of the protocol and the overall approach.
The first description of the reversal of the cognitive decline in patients with early Alzheimer’s disease or its precursors, MCI (mild cognitive impairment) and SCI (subjective cognitive impairment).
We showed that ApoE4 acts as a transcription factor and binds to the promoters of genes involved in a range of processes linked to aging and Alzheimer’s disease pathogenesis. These findings point to novel therapeutic strategies for Alzheimer’s disease and aging, resulting in an extension of human healthspan, and a disease-free and functional period of life.